Fludarabine
Other Solid Tumors
National University Hospital, SingaporeSmall moleculePhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 81/ 100
Competitive context
28 Active assets in the Other Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Evopoint Biosciences Inc. | Phase 1/2 | B |
Epirubicin Karyopharm Therapeutics Inc | Phase 1/2 | B |
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Cyclophosphamide National University Hospital, Singapore | Phase 1/2 | B |
FLUOROURACILUM Karyopharm Therapeutics Inc | Phase 1/2 | CCC |
View all 46 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →